Literature DB >> 21793705

Homocysteine metabolism in polycystic ovary syndrome.

Elena E Grodnitskaya1, Mark A Kurtser.   

Abstract

Homocysteine, a sulfur-containing amino acid formed during the metabolism of methionine, exert cytotoxic effects on vascular endothelium. Molecular mechanisms of homocysteine-induced cellular dysfunction include increased inflammatory cytokine expression, altered nitric oxide bioavailability, induction of oxidative stress, activation of apoptosis and defective methylation. Hyperhomocysteinemia is associated with an increased risk of atherosclerotic and thromboembolic disorders, as well as hyperinsulinemia and may partially account for increased risk of cardiovascular disease associated with insulin resistance. Women with PCOS are more likely to develop components of the metabolic syndrome such as disturbances of carbohydrate metabolism, obesity, hypertension and dyslipidemia, which in turn are risk factors for cardiovascular disease. A number of studies confirmed the presence of increased serum homocysteine concentration in PCOS patients and the possible determinants of this observation are still debated. PCOS treatment options can influence homocysteine levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793705     DOI: 10.3109/09513590.2011.589927

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

1.  Genotype, B-vitamin status, and androgens affect spaceflight-induced ophthalmic changes.

Authors:  Sara R Zwart; Jesse F Gregory; Steven H Zeisel; Charles R Gibson; Thomas H Mader; Jason M Kinchen; Per M Ueland; Robert Ploutz-Snyder; Martina A Heer; Scott M Smith
Journal:  FASEB J       Date:  2015-08-27       Impact factor: 5.191

2.  Serum homocysteine is associated with polycystic ovarian syndrome in Jordan.

Authors:  Nesreen Saadeh; Mahmoud A Alfaqih; Haneen Mansour; Yousef S Khader; Rami Saadeh; Ahmed Al-Dwairi; Mohamad Nusier
Journal:  Biomed Rep       Date:  2018-09-13

Review 3.  Antioxidants and management of polycystic ovary syndrome in Iran: A systematic review of clinical trials.

Authors:  Leila Amini; Najmeh Tehranian; Mansoureh Movahedin; Fahimeh Ramezani Tehrani; Saeedeh Ziaee
Journal:  Iran J Reprod Med       Date:  2015-01

4.  Changes in coagulation and fibrinolytic indices in women with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation.

Authors:  Ying Huang; Yong Zhao; Ling Yan; Yun-Hai Chuai; Ling-Ling Liu; Yi Chen; Min Li; Ai-Ming Wang
Journal:  Int J Endocrinol       Date:  2014-10-13       Impact factor: 3.257

5.  Homocysteine and C-reactive Protein Levels in Women with Polycystic Ovary Syndrome.

Authors:  Murat Gözüküçük; Aslı Yarcı Gürsoy; Emre Destegül; Salih Taşkın; Hakan Şatıroğlu
Journal:  Gynecol Minim Invasive Ther       Date:  2021-11-05

6.  Significant impact of the MTHFR polymorphisms and haplotypes on male infertility risk.

Authors:  Nishi Gupta; Saumya Sarkar; Archana David; Pravin Kumar Gangwar; Richa Gupta; Gita Khanna; Satya Narayan Sankhwar; Anil Khanna; Singh Rajender
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

Review 7.  Association between High Serum Homocysteine Levels and Biochemical Characteristics in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Yuming Meng; Xiang Chen; Zheng Peng; Xuexiang Liu; Yifan Sun; Shengming Dai
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.